Treatment of bipolar depression: Focus on pharmacologic therapies

Expert Review of Neurotherapeutics

Volumn 5, Issue 1, 2005, Pages 69-78

  Mitchell, Philip B ^a   Malhi, Gin S ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antidepressants; Bipolar depression; Cognitive therapy; Electroconvulsive therapy; Lamotrigine; Lithium; Olanzapine; Psychoeducation

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LITHIUM CHLORIDE; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PRAMIPEXOLE; QUETIAPINE; REBOXETINE; VALPROIC ACID;

BIPOLAR DEPRESSION; COCHRANE LIBRARY; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; HYPERLIPIDEMIA; INFORMATION RETRIEVAL; MEDICAL RECORD; MEDLINE; PRACTICE GUIDELINE; REMISSION; REVIEW; SUICIDE ATTEMPT;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS; COGNITIVE THERAPY; DISABILITY EVALUATION; HUMANS; LITHIUM; SUICIDE; TIME FACTORS;

EID: 12344307174     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.1.69     Document Type: Review

References (85)

1. Mitchell PB, Malhi GS. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Dis. 6, 530-539 (2004).
2. Judd LL, Akiskal HS, Schttler PJ, Endicott J, Maser J, Solomon DA. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psych. 59, 530-537 (2002). Large longitudinal study which highlights the high prevalence of depression in bipolar disorder.
3. Judd LL, Akiskal HS, Schuttler PJ, Coryell W, Endicott J, Maser JD. Prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psych. 60, 261-269 (2003).
4. Bauer MS, Kirk GF, Gavin C, Williford WO. Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. J. Affect. Disorders 65, 231-241 (2001).
5. Bryant-Comstock L, Stender M, Devercelli G. Healthcare utilization and costs among privately insured patients with bipolar I disorder. Bipolar Dis. 6, 398-405 (2002).
6. Altshuler LL, Gitlin MJ, Mintz J, Leight KL, Frye MA. Subsyndromal depression is associated with functional impairment inpatients with bipolar disorder. J. Clin. Psychiatry 63, 807-811 (2002).
7. Muller-Oelinghausen B, Berghofer A, Bauer M. Bipolar disorder. Lancet 359, 241-247 (2002).
8. Tondo L, Isacsson G, Baldessarini RJ. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 17, 491-511 (2003).
9. Chen Y-W, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other axis I disorders. Biol. Psychiatry 39, 896-899 (1996).
10. Mitchell PB, Slade T, Andrews G. Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey. Psychol. Med. 34, 777-785 (2004).
11. Kessler RC, Rubinow DR, Holmes C, Abelson JM, Zhao S. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol. Med. 27, 1079-1080 (1997).
12. Goodwin F, Jamison K. Manic-Depressive Illness. Oxford University Press, NY, USA, 1-938 (1990).
13. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. Br. J. Psychiatry 170, 205-228 (1997).
14. Dilsaver SC, Chen Y-W, Swann AC, Shoaib AM, Tsai-Dilsaver Y, Krajewski KJ. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psych. Res. 73, 47-56 (1997).
15. Isometsa ET, Henriksson MM, Aro HM, Lonnqvist JK. Suicide in bipolar disorder in Finland. Am. J. Psychiatry 151, 1020-1024 (1994).
16. Lopez P, Mosquera F, de Leon J et al. Suicide attempts in bipolar patients. J. Clin. Psychiatry 62, 963-966 (2001).
17. Rihmer Z, Kiss K. Bipolar disorders and suicide behaviour. Bipolar Dis. 4, 21-25 (2002).
18. Frankle WG, Perlis RH, Deckersbach T et al. Bipolar depression: relationship between episode length and antidepressant treatment. Psychol. Med. 32, 1417-1423 (2002).
19. Crown WH, Finklenstein S, Berndt ER et al. The impact of treatment-resistant depression on healthcare utilization and costs. J. Clin. Psychiatry 63, 963-971 (2002).
20. Furukawa TA, Konno W, Morinobu S, Harai H, Kitamura T, Takahashi K. Course and outcome of depressive episodes: comparison between bipolar, unipolar and subthreshold depression. Psychiatry Res. 96, 211-220 (2000).
21. Bottlender R, Rudolf D, Jager M, Strauss A, Moller H-J. Are bipolar I depressive patients less responsive to treatment with antidepressants than unipolar depressive patients? Result from a case control study. Eur. Psychiatry 17, 200-205 (2002).
22. Zarate CA, Payne JL, Singh J et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry 56, 54-60 (2004).
23. Hadjipavlou G, Mok H, Yatham LN. Pharmacotherapy of bipolar II disorder: a critical review of current evidence. Bipolar Dis. 6, 14-25 (2004).
24. Bauer MS, Mitchner L. What is a 'mood stabiliser'? An evidence-based response. Am. J. Psychiatry 161, 13-18 (2004).
25. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry 161, 1537-1547 (2004). Important and provocative meta-analysis of the efficacy of antidepressants in bipolar depression, and their propensity to induce mania.
26. Coryell W, Colomon D, Turvey C et al. The long-term course of rapid-cycling bipolar disorder. Arch. Gen. Psych. 60, 914-920 (2003).
27. Malhi GS, Mitchell PB, Salim S. Bipolar depression: management options. CNS Drugs 17, 9-25 (2003).
28. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br. J. Psychiatry 164, 549-550 (1994).
29. Bottlender R, Rudolf D, Straub A, Moller H-J. Mood stabilizers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J. Affect. Disorders 63, 79-83 (2001).
30. Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M. Antidepressant- induced mania in bipolar patients: identification of risk factors. J. Clin. Psychiatry 62, 249-255 (2001).
31. Altshuler L, Suppes T, Black D et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am. J. Psychiatry 160, 1252-1262 (2003).
32. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust. NZ J. Psychiatry 38, 280-305 (2004).
33. Suppes T, Baldessarini RJ, Faedda GL et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch. Gen. Psych. 48, 1082-1088 (1991).
34. Zornberg GL, Pope Jr. HG. Treatment of depression in bipolar disorder: new directions for research. J. Clin. Psychopharmacol. 13, 397-408 (1993).
35. Nemeroff CB, Evans DL, Gyulai L et al. Double -blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am. J. Psychiatry 158, 906-912 (2001).
36. Daly JJ, Prudic J, Devanand DP et al. ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disorders 3, 95-104 (2001).
37. Ballenger JC, Post RM. carbamazepine in manic-depressive illness: a new treatment. Am. J. Psychiatry 137, 782-790 (1980).
38. Post RM, Uhde TW, Roy-Byrne P et al. Antidepressant effects of carbamazepine. Am. J. Psychiatry 143, 29-34 (1986).
39. Post RM, Leverich GS, Denicoff KD et al. Alternative approaches to refractory depression in bipolar illness. Depression Anxiety 5, 73-83 (1997).
40. Dilsaver SC, Swann SC, Chen Y et al. Treatment of bipolar depression with carbamazepine: results of an open study. Biol. Psychiatry 40, 935-937 (1996)
41. Kramlinger KG, Post RM. The addition of lithium to carbamazepine. Arch. Gen. Psych. 46, 794-800 (1989).
42. Post RM, Ketter TA, Denicoff K et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology 128, 115-129 (1996)
43. Young LT, Joffe RT, Robb JC et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am. J. Psychiatry 157, 124-126 (2000).
44. McElroy SL, Keck PE Jr. Treatment guidelines for valproate in bipolar, schizoaffective disorders. Can. J. Psychiatry 38, 62-66 (1993)
45. Winsberg ME, DeGolia SG, Strong CM et al. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J. Affect. Disorders 67, 207-212 (2001).
46. Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry 60, 79-88 (1999). Large controlled study indicating the acute efficacy of lamotrigine in bipolar depression.
47. Frye MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol. 20, 607-614 (2000).
48. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs 63, 2029-2050 (2003).
49. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psych. 60, 1079-1088 (2003). Important controlled study of olanzapine alone and in conjunction with fluoxetine in the acute treatment of bipolar depression.
50. Macfadden W, Calabrese J. Presented at 24th CINP Meeting, June 20-24, Paris, France (2004).
51. Mitchell PB, Wilhelm K, Parker G, Austin M-P, Rutgers P, Malhi GS. The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J. Clin. Psychiatry 62, 212-216 (2001).
52. Singh J, Zarate CA, Krystal AD. Case report: successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. Psychopharmacology 173, 227-228 (2004).
53. Hahn C-G, Gyulai L, Baldassano CF, Lenox RH. The current understanding of lamotrigine as a mood stabilizer. J. Clin. Psychiatry 65, 791-804 (2004).
54. Burgess S, Geddes J, Hawton K et al. Lithium for maintenance treatment of mood disorders (Cochrane Review). The Cochrane Library 4 Update Software, Oxford, UK (2001).
55. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 27, 918-924 (1994).
56. Prien RF, Klett CJ, Caffey EM Jr. Lithium carbonate and imipramine in prevention of affective episodes; a comparison in recurrent affective illness. Arch. Gen. Psych. 29, 420-425 (1973).
57. Kane JM, Quitkin FM, Rifkin A et al. A. Lithium carbonate and Imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch. Gen. Psych. 39, 1065-1069 (1982).
58. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry 161, 217-222 (2004). Important meta-analysis of the relative efficacy of lithium in the prophylaxis of mania and bipolar depression.
59. Macritchie KAN, Geddes JR, Scott J et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Cochrane Review). The Cochrane Library 4 Update Software, Oxford, UK (2001).
60. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled12-month trial of divalproex and lithium in treatment of out-patients with bipolar I disorder. Arch. Gen. Psych. 57, 481-489 (2000). Important report of the prophylactic use of lamotrigine and lithium in bipolar disorder.
61. Dardennes R, Even C, Bange F et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. Br. J. Psychiatry 166, 378-381 (1995).
62. Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr. Scand. 100, 406-417 (1999).
63. Baldessarini RJ. Effects of lithium treatment and its discontinuation on suicidal behaviour in bipolar manic depressive disorders. J Clin. Psychiatry 60, 77-84 (1999).
64. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290, 1467-1473 (2002).
65. Okuma T, Inanaga K, Otsuki S et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology 73, 95-95 (1981).
66. Denicoff KD, Smith-Jackson EE, Disney ER et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J. Clin. Psychiatry 58, 470-478 (1997).
67. Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium vs. carbamazepine in the maintenance treatment of bipolar disorders - a randomized study. J. Affect. Disorders 43, 151-161 (1997).
68. Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28, 1374-1382 (2003).
69. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psych. 60, 392-400 (2003).
70. Calabrese JR, Bowden CL, Sachs G. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar disorder. J. Clin. Psychiatry 64, 1013-1024 (2003).
71. Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J. Clin. Psychiatry 65, 432-441 (2004).
72. Tohen M, Ketter TA, Zarate CA et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am. J. Psychiatry 160, 1263-1271 (2003)
73. Tohen M, Chengappa KN, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs. mood stabiliser alone. Br. J. Psychiatry 184, 337-345 (2004).
74. Tohen M, Marneros A, Bowden C et al. Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Presented at Stanley Foundation Bipolar Network Meeting, September, Freiberg, Germany (2002).
75. Lam DH, Watkins ER, Hayward P. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch. Gen. Psych. 60, 145-152 (2003). Reports a large-scale trial of cognitive therapy for bipolar disorder.
76. Perry A, Tarrier N, Morriss R et al. Randomized controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. Br. Med J. 318, 149-153 (1999).
77. Miklowitz DJ, George EL, Richards, JA et al. A randomized study of family-focused psychoeducation and pharmacotherapy in the out-patient management of bipolar disorder. Arch. Gen. Psych. 60, 904-912 (2003). Report of a controlled trial of a family-based psychoeducational treatment for bipolar disorder relapse prevention.
78. Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch. Gen. Psych. 60, 402-407 (2003). Report of a controlled trial of a patient group psychoeducational treatment for bipolar disorder.
79. Frank E, Kupfer DJ, Ihlers CL et al. Interpersonal and social rhythm therapy for bipolar disorder. Behav. Ther. 17, 143-149 (1994).
80. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: Medication Treatment Of Bipolar Disorder 2000. McGraw-Hill, NY, USA, 1-104 (2000).
81. Boerlin HL, Gitlin MJ, Zoellner LA et al. Bipolar depression and antidepressant-induced mania: a naturalistic study. J. Clin. Psychiatry 59, 374-381 (1998).
82. Bottlender R, Rudolf D, Straub A. Mood-stabilizers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar 1 depressed patients. J. Affect. Disorders 63, 79-83 (2001).
83. Vieta E, Martinez-Aran A, Goikolea JM et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry 63 508-512 (2002).
84. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361, 799-808 (2003).
85. Vieta E, Colom F. Psychological interventions in bipolar disorder: from wishing thinking to an evidence-based approach. Acta Psych. Scandinav. 11 (Suppl. 422), 34-38 (2004).